{"id":"clm_567F86365DD5","entity":"regeneron-pharmaceuticals","predicate":"total_assets","value":"36,086,800,000 United States dollar","value_json":{"fp":"Q2","fy":2024,"accn":"0001804220-24-000028","form":"10-Q","filed":"2024-08-01","period":"Q2 FY2024","concept":"us-gaap:Assets"},"valid_from":"2024-06-30","valid_to":"2024-09-30","published":"2024-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals total assets: 36,086,800,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_567F86365DD5, https://asof.is/claim/clm_567F86365DD5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422024000028/0001804220-24-000028-index.htm.","url":"https://asof.is/claim/clm_567F86365DD5","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_58CF60C9C3BB","supersedes":["clm_89235EAA3408"],"first_seen_at":"2026-11-08T17:08:51.481862+00:00","updated_at":"2026-11-08T17:08:58.955536+00:00","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000180422024000028/0001804220-24-000028-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2024","published_at":"2024-08-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2024, filed 2024-08-01"},"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{},"checked_by":{"sec-filing":"parsed from the SEC filing"}}}